AC
IBRX icon

AlphaCore Capital’s ImmunityBio IBRX Stock Holding History

AlphaCore Capital’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350K Buy
40,028
+25,973
+185% +$197K 0.01% 843
2026
Q1 		$108K Sell
14,055
-2,986,489
-100% -$20.4M ﹤0.01% 916
2025
Q4 		$5.94M Buy
3,000,544
+12,000
+0.4% +$27.2K 0.13% 142
2025
Q3 		$7.35M Buy
2,988,544
+13,666
+0.5% +$35.2K 0.25% 83
2025
Q2 		$7.85M Buy
+2,974,878
New +$8M 0.3% 72

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AlphaCore Capital's IBRX Position: Q2 2026 in Review

AlphaCore Capital increased its ImmunityBio (IBRX) stake by 185% in Q2 2026, buying an estimated $197K and bringing the position to 40,028 shares worth $350K. The position accounts for 0.01% of the portfolio, ranked #843.

AlphaCore Capital first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $7.85M in Q2 2025. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • AlphaCore Capital held 40,028 shares of ImmunityBio worth $350K as of Q2 2026.
  • AlphaCore Capital bought 25,973 ImmunityBio shares in Q2 2026, an estimated $197K.
  • ImmunityBio made up 0.01% of AlphaCore Capital's portfolio in Q2 2026, its #843 holding.
  • AlphaCore Capital first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
  • AlphaCore Capital's ImmunityBio position peaked at $7.85M in Q2 2025.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.